scholarly journals Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications

2020 ◽  
Author(s):  
Filippos Triposkiadis ◽  
Randall C. Starling ◽  
Andrew Xanthopoulos ◽  
Javed Butler ◽  
Harisios Boudoulas
Keyword(s):  
Experimental Evidence ◽  
Observational Studies ◽  
Virus Disease ◽  
Renin Angiotensin System ◽  
Clinical Implications ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Corona Virus

Role of Vitamin D in prevention of Corona virus infection (COVID-19)

2020 ◽  
Vol 11 (SPL1) ◽  
Author(s):  
Surbhi Juneja ◽  
Suwarna Dangore-Khasbage ◽  
Rahul R Bhowate
Keyword(s):  
Vitamin D ◽  
Angiotensin Ii ◽  
Lung Injury ◽  
Cell Injury ◽  
Virus Disease ◽  
Renin Angiotensin System ◽  
Upper Respiratory Tract ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Corona Virus

Corona viruses enveloped positive-sense RNA viruses causes various diseases in mammals as well as birds which range from upper respiratory tract infection to potentially lethal human respiratory syndrome. In humans, Severe Acute Respiratory Syndrome corona virus 2 (SARS-CoV-2) causing corona virus disease 2019 (COVID-19) which shows symptoms like fever, sore throat, gasping and ultimately pneumonia, lung injury and leading to death. The virus acts on various systems of our body, and one of them is the Renin-Angiotensin system. It is supposed that the virus causes cell injury by acting on Angiotensin-Converting Enzyme 2 (ACE2) receptors which causes an increase in the level of Angiotensin II, leading to inflammation and lung injury. An essential vitamin can prevent this in our body that is vitamin D. It acts on Renin-Angiotensin system (RAS) by inhibiting the action of renin and also by increasing production of ACE2 and hence Angiotensin II level decreases which prevent inflammation and lung injury. So vitamin D has a remarkable and pivotal role in modulation of the immune system of our body and hence protects human from this fatal disease.

scholarly journals A Red Wine Vinegar Beverage can Inhibit the Renin-Angiotensin System: Experimental Evidence in Vivo

2005 ◽  
Vol 28 (7) ◽  
pp. 1208-1210 ◽  
Author(s):  
Sachiko Honsho ◽  
Atsushi Sugiyama ◽  
Akira Takahara ◽  
Yoshioki Satoh ◽  
Yuji Nakamura ◽  
...  
Keyword(s):  
Experimental Evidence ◽  
Red Wine ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Wine Vinegar

scholarly journals Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients

2020 ◽  
Author(s):  
Yi Zhang ◽  
Shikai Yu ◽  
Yawei Xu ◽  
Bryan Williams
Keyword(s):  
Systematic Review ◽  
Observational Studies ◽  
Meta Analysis ◽  
Renin Angiotensin System ◽  
Risk Of Infection ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Significant Difference ◽  
The Impact ◽  
Ras Inhibitors

ABSTRACTBackgroundEarly observational studies suggested that the use of the renin angiotensin system (RAS) inhibitors, specifically angiotensin converting enzyme inhibitors or angiotensin receptor blockers, may increase the risk of infection with SARS-CoV-2 and adversely affect the prognosis or survival of infected patients. To explore the impact of RAS inhibitor use on the risk of SARS-CoV-2 infection and the prognosis of SARS-CoV-2 infected patients, from all published studies.Methods and FindingsA systematic review and meta-analysis of the use of RAS inhibitors in relation to infection with SARS-CoV-2 and/or the severity and mortality associated with COVID-19 was conducted. English language bibliographic databases PubMed, Web of Science, OVID Embase, Scopus, MedRxiv, BioRxiv, searched from Jan 1st, 2020 to July 20th, 2020. 58 observational studies (69,200 COVID-19 patients and 3,103,335 controls) were included. There was no difference in the susceptibility to SARS-CoV-2 infection between RAS inhibitor users and non-users (unadjusted OR 1.05, 95% CI 0.90 to 1.21), (adjusted OR 0.93, 95% CI 0.85 to 1.02), (adjusted HR 1.07, 95% CI 0.87 to 1.31). There was no significant difference in the severe Covid-19 case rate between RAS inhibitor users and non-users (unadjusted OR 1.05, 95% CI 0.81 to 1.36), (adjusted OR 0.76, 95% CI 0.52 to 1.12), or in mortality due to COVID-19 between RAS inhibitor users and non-users (unadjusted OR 1.12, 95% CI 0.88 to 1.44), (adjusted OR 0.97, 95% CI 0.77 to 1.23), (adjusted HR 0.62, 95% CI 0.34 to 1.14).ConclusionsIn the most comprehensive analysis of all available data to date, treatment with RAS inhibitors was not associated with increased risk of infection, severity of disease, or mortality due to COVID-19. The best available evidence suggests that these treatments should not be discontinued on the basis of concern about risk associated with COVID-19.

scholarly journals Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications

2020 ◽  
Vol 33 (1) ◽  
pp. 1-5
Author(s):  
Neiberg de Alcantara Lima ◽  
Pedro Yuri Paiva Lima ◽  
Ricardo Lessa de Castro Junior ◽  
Eric Martin Sieloff ◽  
Stela Maria Vitorino Sampaio
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Renin Angiotensin System ◽  
Viral Transmission ◽  
Host Cells ◽  
Angiotensin Receptors ◽  
Clinical Implications ◽  
Converting Enzyme ◽  
Angiotensin System ◽  
Angiotensin Converting Enzyme 2 ◽  
Renin Angiotensin

Initially reported in China at the end of 2019, the coronavirus pandemic has now reached an international scale with more than 1.5 million cases worldwide and more than eighty thousands deaths by April 8th of this year. Recent studies have shown that the virus invades host cells by the angiotensin-converting enzyme 2 receptor, making it essential to viral transmission. Concerns have been raised about possible benefits and harms associated with the use of ACE inhibitors and angiotensin receptors blockers in these patients. However, there is lack of evidence to recommend even temporarily discontinuing renin-angiotensin system inhibitors/blockers in patients infected with the SARS-CoV-2.

Sign in / Sign up

Export Citation Format

Share Document